Bristol Myers Squibb (BMY)
Health Care · Biopharmaceuticals
A diversified biopharmaceutical company leveraging immunotherapy, cell therapies, and small-molecule platforms to address cancer, autoimmune disease, and specialty care.
What Bristol Myers Squibb does
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, and commercializes medicines across oncology, immunology, cardiovascular, and specialty care. The company operates differentiated research platforms including small molecule drugs, biologics, antibody-drug conjugates (ADCs), CAR-T cell therapies, and radiopharmaceutical therapeutics. BMS generates revenue through the sale of approved products and alliance arrangements with other pharmaceutical and biotech partners. As of Q1 2026, the company reported net product sales of $11.2 billion and maintains a portfolio focused on durable competitive advantages through intellectual property and regulatory exclusivity.
Themes: ["Oncology / immuno-oncology","Cancer immunotherapy","CAR-T cell therapies","Checkpoint inhibitors","Autoimmune disease","Multiple myeloma","Non-small cell lung cancer","Melanoma","Cell and gene therapy","Specialty care"]
Fundamentals
- Price$57.94 as of 2026-07-09 close
- Market cap$117.7B as of 2026-07-10
- 1-year return+22.3% as of 2026-07-09 close
- P/E19.69 as of 2026-07-10
- Net margin+12.3% as of 2026-07-10
- Gross margin+53.7% as of 2026-07-10
- ROE+41.6% as of 2026-07-10
- Debt / equity2.22 as of 2026-07-10
- Revenue growth (YoY)+1.8% as of 2026-07-10
- Revenue CAGR (3y)+1.4% SEC XBRL
- Beta0.24 as of 2026-07-10
Dividend: yield +4.4%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Patent expiration and loss of exclusivity on key revenue-generating products such as Opdivo, which faces generic and biosimilar competition","Clinical trial and regulatory approval risk for pipeline programs across multiple therapeutic areas; failure to advance programs could impair future revenue growth","Significant debt burden ($42.2 billion in long-term debt as of Q1 2026) constraining financial flexibility and dividend capacity"]
Competitors & peers
- Merck & Co. (MRK)
- Roche (RHHBY)
- Pfizer (PFE)
- Moderna (MRNA)
- Regeneron (REGN)
- Juno Therapeutics / Celgene
- Gilead Sciences (GILD)
- AstraZeneca (AZN)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.